These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 33224142)
1. The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes. Ding XC; Wang LL; Zhu YF; Li YD; Nie SL; Yang J; Liang H; Weichselbaum RR; Yu JM; Hu M Front Immunol; 2020; 11():580335. PubMed ID: 33224142 [TBL] [Abstract][Full Text] [Related]
2. Correlation of immune phenotype with IDH mutation in diffuse glioma. Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337 [TBL] [Abstract][Full Text] [Related]
3. A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA. Jang BS; Kim IA Radiother Oncol; 2018 Aug; 128(2):245-253. PubMed ID: 29784449 [TBL] [Abstract][Full Text] [Related]
4. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Kim HJ; Park S; Kim KJ; Seong J Radiother Oncol; 2018 Oct; 129(1):130-135. PubMed ID: 29366520 [TBL] [Abstract][Full Text] [Related]
5. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610 [TBL] [Abstract][Full Text] [Related]
7. Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma. Shiraishi T; Toyozumi T; Sakata H; Murakami K; Kano M; Matsumoto Y; Yokoyama M; Okada K; Kamata T; Ryuzaki T; Kinoshita K; Hirasawa S; Matsubara H Oncology; 2022; 100(1):39-47. PubMed ID: 34991094 [TBL] [Abstract][Full Text] [Related]
8. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer. Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759 [TBL] [Abstract][Full Text] [Related]
9. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686 [TBL] [Abstract][Full Text] [Related]
10. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis. Scirocchi F; Strigari L; Di Filippo A; Napoletano C; Pace A; Rahimi H; Botticelli A; Rughetti A; Nuti M; Zizzari IG Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430974 [TBL] [Abstract][Full Text] [Related]
11. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990 [TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467 [TBL] [Abstract][Full Text] [Related]
13. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Oh SY; Kim S; Keam B; Kim TM; Kim DW; Heo DS Sci Rep; 2021 Oct; 11(1):19712. PubMed ID: 34611279 [TBL] [Abstract][Full Text] [Related]
14. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203 [TBL] [Abstract][Full Text] [Related]
15. The influence of plasma sPD-L1 concentration on the effectiveness of immunotherapy in advanced NSCLC patients. Chmielewska I; Grenda A; Krawczyk P; Frąk M; Kuźnar Kamińska B; Mitura W; Milanowski J Cancer Immunol Immunother; 2023 Dec; 72(12):4169-4177. PubMed ID: 37816808 [TBL] [Abstract][Full Text] [Related]
16. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Zhao J; Zhang P; Wang J; Xi Q; Zhao X; Ji M; Hu G Medicine (Baltimore); 2017 Feb; 96(7):e6102. PubMed ID: 28207525 [TBL] [Abstract][Full Text] [Related]
17. The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. Liu S; Zhu Y; Zhang C; Meng X; Sun B; Zhang G; Fan Y; Kang X Front Oncol; 2020; 10():9. PubMed ID: 32038986 [No Abstract] [Full Text] [Related]
18. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies. Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375 [TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400 [TBL] [Abstract][Full Text] [Related]
20. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy. Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]